Climb BioCLYM +3.83%22 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Climb Bio ranks worse than 105820% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Climb Bio's EBITDA for the
three
months ended in Mar. 2026 was $-15.17 Mil. Climb Bio's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Climb Bio's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Climb Bio (NAS:CLYM) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Climb Bio EBITDA Margin % Related Terms
Climb Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Climb Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLYM vs ACRS, CABA, IMMX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Climb Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Climb Bio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Climb Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Climb Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Climb Bio (CLYM) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Climb Bio and its competitors. According to the industry distribution chart, Climb Bio ranks #999999 out of 945 companies in the Biotechnology industry.
Is Climb Bio's EBITDA Margin % too high?
Climb Bio's current EBITDA Margin % is 0.00%. Based on the distribution chart, Climb Bio ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's EBITDA Margin % compare to ACRS and CABA?
According to the Biotechnology industry distribution chart, Climb Bio ranks #999999 out of 945 companies for EBITDA Margin %. This places Climb Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Climb Bio and its competitors. Climb Bio's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Climb Bio's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Climb Bio (CLYM), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score
Get the complete analysis for CLYM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYM has been successfully added to your 
